Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Telix Pharmaceuticals Ltd (TLX.AX)

Telix Pharmaceuticals Ltd (TLX.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Telix Pharmaceuticals Ltd 55 Flemington Road Level 4, North Melbourne Melbourne VIC 3051 AUS

https://www.telixpharma.com P: +61 390933855

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Key Statistics

Overview:

Market Capitalization, $K 3,414,190
Shares Outstanding, K 334,724
% of Institutional Shareholders 26.98%

Financials:

Annual Sales, $ 487,021 K
Annual Net Income, $ 31,041 K

Growth:

1-Year Return -67.08%
3-Year Return 42.65%
5-Year Return 169.54%
5-Year Revenue Growth 188.43%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm 0.02
EPS Growth vs. Prev Year 7.20%
Dividend Payout Ratio 0.00%

TLX.AX Ratios

Ratio
Price/Earnings ttm 308.72
Price/Earnings forward N/A
Return-on-Equity % 2.65%
Return-on-Assets % 1.08%
Profit Margin % 6.37%
Debt/Equity 0.99
Price/Sales 3.91
Price/Book 5.71
Book Value/Share 1.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar